Intensive chemotherapy for metastatic nonseminomatous germ cell tumors.
Logothetis
C J
CJ
Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Chong
C
C
Dexeus
F H
FH
Sella
A
A
Ogden
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D006063:Chorionic Gonadotropin / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007196:Indiana / Q000453:epidemiology; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010446:Peptide Fragments / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D013781:Texas / Q000453:epidemiology; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments; D001761:Bleomycin; D014747:Vinblastine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin